DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20221790
Published: 2022-06-28

Safety and efficacy of intraoperative Mitomycin C in pterygium

Araf Ali, Ourfa Ashraf, Sheikh Sajjad

Abstract


Background: Pterygium recurrence rate after simple surgical excision is high. Many adjunctive treatments have been used to reduce the recurrence rates of pterygium development. This study was designed to evaluate the results of intraoperative use of Mitomycin C in patients with single recurrence of pterygium.

Methods: this was a hospital based prospective study conducted in the department of ophthalmology SKIMS-MCH, Srinagar from January 2021 to December 2021. 30 eyes of 30 patients who had single recurrence of pterygium after excision underwent pterygium excision along-with concurrent use of intraoperative 0.04% Mitomycin C. Postoperative follow up was done for a period of 6 months.

Results: A total of 30 eyes of 30 patients were taken (16 males patients and 14 female patients) with 16 right eyes and 14 left eyes. Recurrence was seen in 3 patients, two males and 1 female at 4 weeks, 6 weeks and 8 weeks respectively. The side effects encountered were ocular discomfort, foreign body sensation, chemosis and hyperaemia.

Conclusions: Intraoperative use of Mitomycin C in treatment of recurrent pterygium is safe and effective procedure.

 


Keywords


Pterygium, Mitomycin C, Pterygium recurrence

Full Text:

PDF

References


Rosenthal JW. Chronology of pterygium therapy. Am J Ophthalmol. 1953;36(11):1601-16.

Moran DJ, Hollows FC. Pterygium and ultraviolet radiation: a positive correlation. Br J Ophthalmol. 1984;68(5):343-6.

Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007;18(4):308-13.

Nangia V, Jonas JB, Nair D, Saini N, Nangia P, Panda-Jonas S. Prevalence and associated factors for pterygium in rural agrarian central India. The central India eye and medical study. PLoS One. 2013;8(12): e82439.

Zeng W, Liu Z, Dai H, Yan M, Luo H, Ke M, et al. Anti-fibrotic, anti-VEGF or radiotherapy treatments as adjuvants for pterygium excision: a systematic review and network meta-analysis. BMC Ophthalmol. 2017;17(1):211.

D'Ombrain A. The surgical treatment of pterygium. Br J Ophthalmol. 1948;32(2):65-71.

Alpay A, Uğurbaş SH, Erdoğan B. Comparing techniques for pterygium surgery. Clin Ophthalmol. 2009;3:69-74.

Kareem AA, Farhood QK, Alhammami HA. The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium. Clin Ophthalmol. 2012;6:1849-54.

Verma N, Garap JA, Maris R, Kerek A. Intraoperative use of mitomycin C in the treatment of recurrent pterygium. P N G Med J. 1998;41(1):37-42.

Yanyali AC, Talu H, Alp BN, Karabas L, Ay GM, Caglar Y. Intraoperative mitomycin C in the treatment of pterygium. Cornea. 2000;19(4):471-3.

Demirok A, Simsek S, Cinal A, Yasar T. Intraoperative application of mitomycin C in the surgical treatment of pterygium. Eur J Ophthalmol. 1998;8(3):153-6.

Peng ML, Tsai YY, Tung JN, Chiang CC, Huang YC, Lee H. Vascular endothelial growth factor gene polymorphism and protein expression in the pathogenesis of pterygium. Br J Ophthalmol. 2014; 98:556-61.